Brought to you by 
Schwarz to develop and market Harris' Harkoseride
17 Jan 2000
Executive Summary
Schwarz (cardiovascular, gastrointestinal, urologic drugs) will complete the development and market worldwide, with the exception of Japan, drug development company Harris' Harkoseride, a Phase II anticonvulsant drug to treat epilepsy and neurogenic pain.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Schwarz to develop and market Harris' Harkoseride
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice